EGFR and lung adenocarcinoma: Furthermore, for patients with EGFR mutation-positive lung adenocarcinoma who developed acquired resistance to erlotinib or gefitinib, drug efficacy to the original TKI can be recovered when combining with conventional chemotherapy (43).